Navigation Links
Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 Patients
Date:9/1/2013

THOUSAND OAKS, Calif., Aug. 31, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced treatment with AMG 145 resulted in significant reductions in low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, of up to 59 percent in an efficacy analysis of pooled data from four 12-week Phase 2 studies evaluating AMG 145 in patient populations with high cholesterol. AMG 145 is an investigational human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. Amgen presented the data at the ESC Congress 2013, organized by the European Society of Cardiology, in Amsterdam.

Elevated LDL-C is recognized as a major risk factor for cardiovascular (CV) disease.1,2 Despite the availability of various treatments to lower LDL-C, it is estimated that in two-thirds of treated, high-risk patients, LDL-C is not well-controlled.3,4

"Millions of people around the world are unable to control their LDL cholesterol with currently available treatment options," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The data that we have accumulated in our Phase 2 clinical program is evidence that AMG 145 has the potential to help patients reach their cholesterol goals. We are conducting a large and comprehensive Phase 3 clinical program evaluating AMG 145 in multiple patient populations and utilizing two dosing schedules, with the hopes of advancing care and improving the lives of patients with uncontrolled high LDL cholesterol."

Results from the efficacy analysis showed mean reductions in LDL-C from baseline to week 12, as measured by preparative ultracentrifugation, ranged from 40 to 59 percent across AMG 145 doses in comparison to 0.1 to 0.5 percent for placebo (p=0.001).
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Report presents designs for study of cancer risks near US nuclear facilities
2. NYU School of Medicine presents 2012 Dart/NYU Biotechnology Achievement Awards
3. John Theurer Cancer Center presents significant blood cancer research at 2012 ASCO Annual Meeting
4. GSA Bulletin presents studies in Antarctica, Italy, Mexico, Algeria, Mongolia, and more
5. Crop Science Society of America presents 2012 class of fellows
6. IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management
7. Choline supplementation during pregnancy presents a new approach to schizophrenia prevention
8. July meeting presents animal and dairy science
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Beyond the microscope: Identifying specific cancers using molecular analysis
11. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... new study that could ultimately lead to many new ... Research Institute (TSRI) have adapted a chemical approach to ... that can treat a form of muscular dystrophy. , ... a disease-causing defect as a catalyst to synthesize a ... Disney.,"Because the treatment is synthesized only in diseased cells, ...
(Date:9/2/2014)... the same DNA sequence their genetic information. How ... in the different parts of the body are so ... master plan, an additional regulatory layer exists that determines ... This mechanism involves modifications of genome-bound histone proteins or ... It acts on top of the genetic information and ...
(Date:9/2/2014)... the September issue of The FASEB Journal ... to diagnose the leading cause of blindness in ... occurred. This advance involves quantifying the early molecular ... retinal vessels. Using new probes developed by scientists, ... development of diabetic retinopathy. , "My goal is ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Throwing a loop to silence gene expression 2Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... Scientists have discovered that a stem cell factor overexpressed ... brain injury promotes tumor survival by inducing angiogenesis. The ... Cell, examines the interaction between tumor cells and surrounding ... more effective therapeutics for one of the most lethal ...
... In an unexpected discovery, scientists at Jefferson Medical College ... virus protein can turn a "safe" virus extremely deadly. ... vaccine they previously created against rabies in wildlife, making ... a molecular mechanism involved in making the rabies virus ...
... disease in the brain of the fruit fly, researchers ... proteins previously associated with cancer. , The findings are ... Brigham and Women's Hospital, Harvard Medical School, and the ... not divide. It is therefore perplexing that in Alzheimer's ...
Cached Biology News:Growth factor-promoting angiogenesis expressed in tumor cells and normal neurons 2Jefferson researchers building a better rabies vaccine 2
(Date:9/2/2014)... Victoria, Australia (PRWEB) September 02, 2014 ... provide a cure for chronic tinnitus are seeking support ... run on the Indiegogo platform ( http://igg.me/at/tinaway ), was ... to be a therapeutic ‘mHealth’ app and is based ... brainchild of a team of biomedical and software engineers, ...
(Date:9/1/2014)... NewYork (PRWEB) September 01, 2014 ... Biotech and Diagnostics report provides comprehensive understanding and ... agreements entered into by the worlds leading life ... understand and analysis of how and why companies ... of a prospective partner’s negotiated deals terms provides ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
Breaking Biology Technology:tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Innovation, Inc. (BHI), a regional private-public partnership focusing ... early-stage funding in Central Maryland, announced today the appointment ... at Qiagen , to its Board of ... to our board," said Scott Carmer, BioHealth Innovation, Inc. ...
... by Kathleen Eggleson, a research scientist in the Center ... of Notre Dame, provides an example of a nanotechnology-related ... The world of nanotechnology, which involves science and ... But like most new advances, the application of that ...
... On April 19, 2012, GeneLink,s common stock began trading ... this will be temporary as it is due to the ... for the period ended December 31, 2011.  The Company anticipates ... on Form 10K for the period ended December 31, 2011 ...
Cached Biology Technology:BioHealth Innovation, Inc. Appoints Qiagen's Douglas Liu to Board of Directors 2Notre Dame paper examines nanotechnology-related safety and ethics problem 2Notre Dame paper examines nanotechnology-related safety and ethics problem 3GeneLink Anticipates Completion of Audit 2
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Human peripheral blood CD56+ NK cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
Biology Products: